HSBC/CALL/MODERNA/280/0.1/15.01.25 | Market Closed - Bid/Ask 03:35:36 2024-05-27 pm EDT | After market 03:59:31 pm | |||
| 0.66 EUR | 0.00% |
|
0.685 | +3.79% |
| Current month | +671.08% | ||
| 1 month | +801.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-27 | 0.66 | 0.00% |
| 24-05-24 | 0.66 | +8.20% |
| 24-05-23 | 0.61 | +1.67% |
| 24-05-22 | 0.6 | +150.00% |
| 24-05-21 | 0.24 | +14.29% |
Real-time Boerse Frankfurt Warrants
Last update May 27, 2024 at 03:35 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | HSBC |
| WKN | HG807N |
| ISIN | DE000HG807N7 |
| Date issued | 2023-02-02 |
| Strike | 280 $ |
| Maturity | 2025-01-15 (233 Days) |
| Parity | 10 : 1 |
| Emission price | 2.91 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.77 € |
|---|---|
| Lowest since issue | 0.029 € |
| Spread | 0.03 € |
| Spread % | 4.29% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
166.6
USD
Average target price
138.5
USD
Spread / Average Target
-16.86%
- Stock Market
- Warrants
- Warrant
